Company Analysis Genscript Biotech Corporation
1. Summary
Advantages
- Price (13.06 HK$) is less than fair price (15.34 HK$)
Disadvantages
- Dividends (0%) are below the sector average (5.7%).
- The stock's return over the last year (-17.34%) is lower than the sector average (20.13%).
- Current debt level 19.37% has increased over 5 years from 2.11%.
- The company's current efficiency (ROE=-7.95%) is lower than the sector average (ROE=4.42%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Genscript Biotech Corporation | Healthcare | Index | |
|---|---|---|---|
| 7 days | 5% | 8.2% | -5.6% |
| 90 days | 33.4% | 23.9% | 16.2% |
| 1 year | -17.3% | 20.1% | 41.5% |
1548 vs Sector: Genscript Biotech Corporation has significantly underperformed the "Healthcare" sector by -37.47% over the past year.
1548 vs Market: Genscript Biotech Corporation has significantly underperformed the market by -58.83% over the past year.
Stable price: 1548 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 1548 with weekly volatility of -0.3335% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (13.06 HK$) is lower than the fair price (15.34 HK$).
Price not significantly lower than the fair price: The current price (13.06 HK$) is slightly lower than the fair price by 17.5%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (36.59).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (26.8).
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.54) is lower than that of the sector as a whole (3.66).
P/BV vs Market: The company's P/BV (2.54) is higher than that of the market as a whole (-11.95).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (6.18) is lower than that of the sector as a whole (7.13).
P/S vs Market: The company's P/S indicator (6.18) is higher than that of the market as a whole (2.7).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-93.49) is lower than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (-93.49) is lower than that of the market as a whole (9.94).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -10.68% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-10.68%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (83.09%).
5.4. ROE
ROE vs Sector: The company's ROE (-7.95%) is lower than that of the sector as a whole (4.42%).
ROE vs Market: The company's ROE (-7.95%) is lower than that of the market as a whole (5.98%).
5.5. ROA
ROA vs Sector: The company's ROA (-3.22%) is lower than that of the sector as a whole (2.95%).
ROA vs Market: The company's ROA (-3.22%) is lower than that of the market as a whole (3.18%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '5.7%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
